FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs
This article was originally published in The Tan Sheet
Executive Summary
FDA's announcement it is investigating a possible risk of liver injury related to orlistat - the active ingredient in Roche Pharmaceuticals' prescription weight-loss drug Xenical and GlaxoSmithKline's OTC alli - could threaten short-term sales
You may also be interested in...
Alli Recall Could Help Mitigate Reputation Damage In Face Of Tampering
GSK investigates tampering with its alli weight-loss drug and positions itself as a consumer advocate with a U.S. recall of the product. By showing it is “on the side of good,” the firm could actually emerge from the crisis with a stronger reputation, crisis management expert Gene Grabowski says.
Alli Recall Could Help Mitigate Reputation Damage In Face Of Tampering
GSK investigates tampering with its alli weight-loss drug and positions itself as a consumer advocate with a U.S. recall of the product. By showing it is “on the side of good,” the firm could actually emerge from the crisis with a stronger reputation, crisis management expert Gene Grabowski says.
Alli Recall Could Help Mitigate Reputation Damage In Face Of Tampering
GSK investigates tampering with its alli weight-loss drug and positions itself as a consumer advocate with a U.S. recall of the product. By showing it is “on the side of good” the firm could actually emerge from the crisis with a stronger reputation, says crisis management expert Gene Grabowski says.